Pain and withdrawal are common among patients receiving medications for opioid use disorder and associated with pain catastrophizing, negative affect, and poor sleep.

IF 2.4 3区 医学 Q3 PHARMACOLOGY & PHARMACY Experimental and clinical psychopharmacology Pub Date : 2024-08-01 Epub Date: 2024-05-09 DOI:10.1037/pha0000723
Meredith S Berry, Kelly E Dunn
{"title":"Pain and withdrawal are common among patients receiving medications for opioid use disorder and associated with pain catastrophizing, negative affect, and poor sleep.","authors":"Meredith S Berry, Kelly E Dunn","doi":"10.1037/pha0000723","DOIUrl":null,"url":null,"abstract":"<p><p>Substantial percentages of persons receiving medications for opioid use disorder (MOUD) continue to experience clinically significant levels of pain and opioid withdrawal, which may pose barriers to reducing opioid use. Continued pain, in particular, may increase the risk for psychiatric problems and poorer treatment retention, especially with a lack of adequate care for pain. The goals of these analyses were to characterize the prevalence of, and patient-level variables associated with, pain and opioid withdrawal, as well as utilization of related coping strategies and treatments. Participants were 18 years of age or older and received methadone or buprenorphine for opioid use disorder (<i>n</i> = 179). Participants completed this survey in person, within their MOUD clinic. Participants completed patient-level and demographic questions as well as measures of pain, withdrawal, utilization of related coping strategies, and pain treatment. Numerous participants endorsed chronic pain (41.9%) or opioid withdrawal (89.4%) and indicated reliance upon over-the-counter medications and prayer for pain management. Multiple linear regression models showed greater pain catastrophizing and negative affect accounted for variability in pain severity and pain interference, as well as opioid withdrawal. Persons who slept less and endorsed chronic pain also reported greater pain severity and interference, and pain interference was higher with increased age. These and previous findings combine to further highlight the detrimental role that pain catastrophizing and negative affect can play in pain perception and withdrawal, but also represent promising treatment targets to facilitate pain and withdrawal management and improved quality of life. (PsycInfo Database Record (c) 2024 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11513174/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and clinical psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1037/pha0000723","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Substantial percentages of persons receiving medications for opioid use disorder (MOUD) continue to experience clinically significant levels of pain and opioid withdrawal, which may pose barriers to reducing opioid use. Continued pain, in particular, may increase the risk for psychiatric problems and poorer treatment retention, especially with a lack of adequate care for pain. The goals of these analyses were to characterize the prevalence of, and patient-level variables associated with, pain and opioid withdrawal, as well as utilization of related coping strategies and treatments. Participants were 18 years of age or older and received methadone or buprenorphine for opioid use disorder (n = 179). Participants completed this survey in person, within their MOUD clinic. Participants completed patient-level and demographic questions as well as measures of pain, withdrawal, utilization of related coping strategies, and pain treatment. Numerous participants endorsed chronic pain (41.9%) or opioid withdrawal (89.4%) and indicated reliance upon over-the-counter medications and prayer for pain management. Multiple linear regression models showed greater pain catastrophizing and negative affect accounted for variability in pain severity and pain interference, as well as opioid withdrawal. Persons who slept less and endorsed chronic pain also reported greater pain severity and interference, and pain interference was higher with increased age. These and previous findings combine to further highlight the detrimental role that pain catastrophizing and negative affect can play in pain perception and withdrawal, but also represent promising treatment targets to facilitate pain and withdrawal management and improved quality of life. (PsycInfo Database Record (c) 2024 APA, all rights reserved).

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在接受阿片类药物治疗的患者中,疼痛和戒断是常见现象,并与疼痛灾难化、消极情绪和睡眠不佳有关。
在接受阿片类药物使用障碍(MOUD)药物治疗的患者中,有相当大比例的人仍会出现临床上明显的疼痛和阿片类药物戒断症状,这可能会对减少阿片类药物的使用构成障碍。尤其是持续的疼痛可能会增加出现精神问题的风险,并降低治疗的持续性,特别是在缺乏对疼痛的适当护理的情况下。这些分析的目的是确定疼痛和阿片类药物戒断的发生率、与疼痛和阿片类药物戒断相关的患者水平变量,以及相关应对策略和治疗方法的使用情况。参与者年龄在 18 岁或以上,接受美沙酮或丁丙诺啡治疗阿片类药物使用障碍(n = 179)。参与者在其 MOUD 诊所内亲自完成了这项调查。参与者填写了患者层面和人口统计学问题,以及疼痛、戒断、相关应对策略的使用和疼痛治疗的测量。许多参与者表示有慢性疼痛(41.9%)或阿片类药物戒断(89.4%),并表示依赖非处方药和祈祷来控制疼痛。多元线性回归模型显示,更严重的疼痛灾难化和负面情绪导致了疼痛严重程度和疼痛干扰以及阿片类药物戒断的变化。睡眠较少且认可慢性疼痛的人也报告了更大的疼痛严重性和干扰,年龄越大,疼痛干扰越大。这些研究结果与之前的研究结果相结合,进一步凸显了疼痛灾难化和负面情绪在疼痛感知和戒断中的不利作用,同时也是促进疼痛和戒断管理以及提高生活质量的有前途的治疗目标。(PsycInfo Database Record (c) 2024 APA,保留所有权利)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.20
自引率
8.70%
发文量
164
审稿时长
6-12 weeks
期刊介绍: Experimental and Clinical Psychopharmacology publishes advances in translational and interdisciplinary research on psychopharmacology, broadly defined, and/or substance abuse.
期刊最新文献
Evaluating the human abuse potential of concurrent use of electronic cigarettes and low nicotine cigarettes among adults who smoke. Residual next-day effects of alprazolam on psychomotor performance and simulated driving in healthy normal adults. Efficacy and safety of balovaptan for posttraumatic stress disorder: A randomized, placebo-controlled trial. A behavioral choice analysis of the role of life events during early nonabstinent natural recovery from alcohol use disorder. An experimental investigation into the impact of acute stress on alcohol craving.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1